Kate Farrell, PhD, is the CEO and Co-Founder of Paradigm Shift Therapeutics, LLC which was established in January 2014. She is a veteran of Amgen, having worked there from 1992-2007 in a variety of roles, the most recent being head of Global Clinical Supply Chain Management. Prior to this, she was the Oncology Therapeutic Area Head in Global Operations Planning. She also worked in Medical Affairs on a product launch, and was Product Team Leader during the transition of a pipeline product from Phase 2 to 3. Her first 8 years at Amgen were as a research scientist in the preclinical division working on discovery projects and on product teams across a variety of therapeutic areas. From 2008 to 2013 Kate worked as a consultant doing preclinical product development (part-time) for the Novel Therapeutics division of Epistem, a UK-based biotechnology company focused on epithelial stem cell biology, as well as other short term consulting projects. She has a Ph.D. in Biophysics from the University of Western Ontario in London, ON, Canada, and was a Medical Research Council of Canada Post Doctoral Fellow initially at UCLA, and then at the Max Plank Institute in Munich, Germany.